Listing of drug delivery device patents in the USFDA’s Orange Book: What the patent drafters can learn from Lantus^® soloSTAR^® device lawsuit?

Click to increase image sizeClick to decrease image size

Funding

This paper was not funded.

Acknowledgments

The author would like to thank the diligent taxpayers of India and NIPER-Hyderabad for providing resources to prepare the present manuscript (NIPER-H/2021/201).

Declaration of interests

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.